MarketPulse

Phase 1 study

2 articles
BenzingaBenzinga··Vandana Singh

AbbVie's Obesity Drug Shows Promise With Up to 10% Weight Loss in Early Trial

AbbVie reports Phase 1 data for obesity treatment ABBV-295, showing 7.75%-9.79% weight loss. Stock declined despite positive results amid broader market pressure.
ABBVXLVIYHclinical trialweight loss
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Aligos Presents Clinical Advances in Hepatitis B and Coronavirus Inhibitor Programs

Aligos presented clinical progress for hepatitis B and coronavirus treatments at CROI. Pevifoscorvir showed strong viral suppression, while ALG-097558 provided dosing data for impaired patients.
ALGSclinical trialhepatitis B virus (HBV)